⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 13, 2024Open Access

Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors

Constance A. Sobsey Bjoern C. Froehlich Georgia Mitsa Sahar Ibrahim Robert Popp René P. Zahedi Elza C. de Bruin Christoph H. Borchers Gerald Batist

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Combination treatment of cell lines with capivasertib and an eIF2α inhibitor

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sobsey et al. (2024) studied this question.

synapsesocial.com/papers/68e5c85eb6db64358755f0ed https://doi.org/10.1158/2767-9764.26553474.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024
2Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024
3Supplementary Figure S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024
4Supplementary Figure S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024
5Supplementary Figure S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024

More related papers

Supplementary Figure S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024
Supplementary Figure S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024
Supplementary Figure S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors2024